Selected research
Industry Research
Erlotinib Industry Research Report 2026
Market perspective
The global Erlotinib market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Erlotinib is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Erlotinib is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Erlotinib is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Erlotinib include Sichuan Xieli Pharmaceutical, Lunarsun Pharmaceutical, Boyuan Pharmaceutical, Teva, Sakar Healthcare, Nishchem International, Murli Krishna Pharma, Laurus Labs and HRV Global, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Erlotinib market in terms of revenue (US$ million) and, where applicable, sales volume (Tons), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/Tons) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Erlotinib Market by Company
Sichuan Xieli Pharmaceutical
Lunarsun Pharmaceutical
Boyuan Pharmaceutical
Teva
Sakar Healthcare
Nishchem International
Murli Krishna Pharma
Laurus Labs
HRV Global
Gonane Pharma
EstechPharma
CDYMAX
Aspen Biopharma Labs
Acebright
Erlotinib Segment by Type
Below 98%
Above 98%
Erlotinib Segment by Application
Pharmaceutical
Chemical
Others
Erlotinib Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Erlotinib market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Erlotinib and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Erlotinib.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Erlotinib manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Erlotinib by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Erlotinib in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Below 98%
- Above 98%
Applications
- Pharmaceutical
- Chemical
- Others
Companies covered
- Sichuan Xieli Pharmaceutical
- Lunarsun Pharmaceutical
- Boyuan Pharmaceutical
- Teva
- Sakar Healthcare
- Nishchem International
- Murli Krishna Pharma
- Laurus Labs
- HRV Global
- Gonane Pharma
- EstechPharma
- CDYMAX
- Aspen Biopharma Labs
- Acebright
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Erlotinib Market Size (2021-2032)
- 2.2.2 Global Erlotinib Sales (2021-2032)
- 2.2.3 Global Erlotinib Market Average Price (2021-2032)
- 2.3 Erlotinib by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Below 98%
- 2.3.3 Above 98%
- 2.4 Erlotinib by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Pharmaceutical
- 2.4.3 Chemical
- 2.4.4 Others
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Erlotinib Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Erlotinib Sales (Tons) of Manufacturers (2021-2026)
- 3.3 Global Erlotinib Revenue of Manufacturers (2021-2026)
- 3.4 Global Erlotinib Average Price by Manufacturers (2021-2026)
- 3.5 Global Erlotinib Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Erlotinib, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Erlotinib, Product Type & Application
- 3.8 Global Manufacturers of Erlotinib, Established Date
- 3.9 Global Erlotinib Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Sichuan Xieli Pharmaceutical
- 4.1.1 Sichuan Xieli Pharmaceutical Company Information
- 4.1.2 Sichuan Xieli Pharmaceutical Business Overview
- 4.1.3 Sichuan Xieli Pharmaceutical Erlotinib Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Sichuan Xieli Pharmaceutical Erlotinib Product Portfolio
- 4.1.5 Sichuan Xieli Pharmaceutical Recent Developments
- 4.2 Lunarsun Pharmaceutical
- 4.2.1 Lunarsun Pharmaceutical Company Information
- 4.2.2 Lunarsun Pharmaceutical Business Overview
- 4.2.3 Lunarsun Pharmaceutical Erlotinib Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Lunarsun Pharmaceutical Erlotinib Product Portfolio
- 4.2.5 Lunarsun Pharmaceutical Recent Developments
- 4.3 Boyuan Pharmaceutical
- 4.3.1 Boyuan Pharmaceutical Company Information
- 4.3.2 Boyuan Pharmaceutical Business Overview
- 4.3.3 Boyuan Pharmaceutical Erlotinib Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Boyuan Pharmaceutical Erlotinib Product Portfolio
- 4.3.5 Boyuan Pharmaceutical Recent Developments
- 4.4 Teva
- 4.4.1 Teva Company Information
- 4.4.2 Teva Business Overview
- 4.4.3 Teva Erlotinib Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Teva Erlotinib Product Portfolio
- 4.4.5 Teva Recent Developments
- 4.5 Sakar Healthcare
- 4.5.1 Sakar Healthcare Company Information
- 4.5.2 Sakar Healthcare Business Overview
- 4.5.3 Sakar Healthcare Erlotinib Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Sakar Healthcare Erlotinib Product Portfolio
- 4.5.5 Sakar Healthcare Recent Developments
- 4.6 Nishchem International
- 4.6.1 Nishchem International Company Information
- 4.6.2 Nishchem International Business Overview
- 4.6.3 Nishchem International Erlotinib Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Nishchem International Erlotinib Product Portfolio
- 4.6.5 Nishchem International Recent Developments
- 4.7 Murli Krishna Pharma
- 4.7.1 Murli Krishna Pharma Company Information
- 4.7.2 Murli Krishna Pharma Business Overview
- 4.7.3 Murli Krishna Pharma Erlotinib Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Murli Krishna Pharma Erlotinib Product Portfolio
- 4.7.5 Murli Krishna Pharma Recent Developments
- 4.8 Laurus Labs
- 4.8.1 Laurus Labs Company Information
- 4.8.2 Laurus Labs Business Overview
- 4.8.3 Laurus Labs Erlotinib Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Laurus Labs Erlotinib Product Portfolio
- 4.8.5 Laurus Labs Recent Developments
- 4.9 HRV Global
- 4.9.1 HRV Global Company Information
- 4.9.2 HRV Global Business Overview
- 4.9.3 HRV Global Erlotinib Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 HRV Global Erlotinib Product Portfolio
- 4.9.5 HRV Global Recent Developments
- 4.10 Gonane Pharma
- 4.10.1 Gonane Pharma Company Information
- 4.10.2 Gonane Pharma Business Overview
- 4.10.3 Gonane Pharma Erlotinib Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Gonane Pharma Erlotinib Product Portfolio
- 4.10.5 Gonane Pharma Recent Developments
- 4.11 EstechPharma
- 4.11.1 EstechPharma Company Information
- 4.11.2 EstechPharma Business Overview
- 4.11.3 EstechPharma Erlotinib Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 EstechPharma Erlotinib Product Portfolio
- 4.11.5 EstechPharma Recent Developments
- 4.12 CDYMAX
- 4.12.1 CDYMAX Company Information
- 4.12.2 CDYMAX Business Overview
- 4.12.3 CDYMAX Erlotinib Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 CDYMAX Erlotinib Product Portfolio
- 4.12.5 CDYMAX Recent Developments
- 4.13 Aspen Biopharma Labs
- 4.13.1 Aspen Biopharma Labs Company Information
- 4.13.2 Aspen Biopharma Labs Business Overview
- 4.13.3 Aspen Biopharma Labs Erlotinib Sales, Revenue and Gross Margin (2021-2026)
- 4.13.4 Aspen Biopharma Labs Erlotinib Product Portfolio
- 4.13.5 Aspen Biopharma Labs Recent Developments
- 4.14 Acebright
- 4.14.1 Acebright Company Information
- 4.14.2 Acebright Business Overview
- 4.14.3 Acebright Erlotinib Sales, Revenue and Gross Margin (2021-2026)
- 4.14.4 Acebright Erlotinib Product Portfolio
- 4.14.5 Acebright Recent Developments
5 Global Erlotinib Market Scenario by Region
- 5.1 Global Erlotinib Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Erlotinib Sales by Region: 2021-2032
- 5.2.1 Global Erlotinib Sales by Region: 2021-2026
- 5.2.2 Global Erlotinib Sales by Region: 2027-2032
- 5.3 Global Erlotinib Revenue by Region: 2021-2032
- 5.3.1 Global Erlotinib Revenue by Region: 2021-2026
- 5.3.2 Global Erlotinib Revenue by Region: 2027-2032
- 5.4 North America Erlotinib Market Facts & Figures by Country
- 5.4.1 North America Erlotinib Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Erlotinib Sales by Country (2021-2032)
- 5.4.3 North America Erlotinib Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Erlotinib Market Facts & Figures by Country
- 5.5.1 Europe Erlotinib Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Erlotinib Sales by Country (2021-2032)
- 5.5.3 Europe Erlotinib Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Erlotinib Market Facts & Figures by Country
- 5.6.1 Asia Pacific Erlotinib Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Erlotinib Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Erlotinib Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Erlotinib Market Facts & Figures by Country
- 5.7.1 South America Erlotinib Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Erlotinib Sales by Country (2021-2032)
- 5.7.3 South America Erlotinib Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Erlotinib Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Erlotinib Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Erlotinib Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Erlotinib Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Erlotinib Sales by Type (2021-2032)
- 6.1.1 Global Erlotinib Sales by Type (2021-2032) & (Tons)
- 6.1.2 Global Erlotinib Sales Market Share by Type (2021-2032)
- 6.2 Global Erlotinib Revenue by Type (2021-2032)
- 6.2.1 Global Erlotinib Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Erlotinib Revenue Market Share by Type (2021-2032)
- 6.3 Global Erlotinib Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Erlotinib Sales by Application (2021-2032)
- 7.1.1 Global Erlotinib Sales by Application (2021-2032) & (Tons)
- 7.1.2 Global Erlotinib Sales Market Share by Application (2021-2032)
- 7.2 Global Erlotinib Revenue by Application (2021-2032)
- 7.2.1 Global Erlotinib Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Erlotinib Revenue Market Share by Application (2021-2032)
- 7.3 Global Erlotinib Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Erlotinib Value Chain Analysis
- 8.1.1 Erlotinib Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Erlotinib Production Mode & Process
- 8.2 Erlotinib Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Erlotinib Distributors
- 8.2.3 Erlotinib Customers
9 Global Erlotinib Analyzing Market Dynamics
- 9.1 Erlotinib Industry Trends
- 9.2 Erlotinib Industry Drivers
- 9.3 Erlotinib Industry Opportunities and Challenges
- 9.4 Erlotinib Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst